| 发明名称 | Antisense modulation of GCCR expression | ||
| 摘要 | Provided herein are methods, compounds, and compositions for reducing expression of GCCR mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate metabolic disease, for example, diabetes, or a symptom thereof. | ||
| 申请公布号 | US9567587(B2) | 申请公布日期 | 2017.02.14 |
| 申请号 | US201414523751 | 申请日期 | 2014.10.24 |
| 申请人 | Ionis Pharmaceuticals, Inc. | 发明人 | Freier Susan M.;Bhanot Sanjay |
| 分类号 | C07H21/02;C07H21/04;A61K31/70;C12N15/113;A61K31/7088;A61K45/06;A61K31/7115;A61K31/712;A61K31/7125;C12N5/00 | 主分类号 | C07H21/02 |
| 代理机构 | Ionis Pharmaceuticals, Inc. Patent Dept. | 代理人 | Ionis Pharmaceuticals, Inc. Patent Dept. |
| 主权项 | 1. A compound comprising a modified antisense oligonucleotide consisting of 12 to 30 linked nucleosides having a nucleobase sequence comprising a portion of at least 8 contiguous nucleobases complementary to an equal length portion of nucleobases 51878-51898, 60935-60958, 104247-104266, 109346-109492, 112218-112242, 114154-114610, 139287-139306, 143259-143757 of SEQ ID NO: 1, wherein the nucleobase sequence of the modified antisense oligonucleotide is at least 90% complementary to SEQ ID NO: 1 and wherein the modified antisense oligonucleotide inhibits GCCR expression. | ||
| 地址 | Carlsbad CA US | ||